On May 21, 2026, Immix Biopharma, Inc. disclosed the pricing details of its underwritten registered offering. The offering consists of 16,778,524 shares of common stock priced at $8.94 per share for a total of $150 million in gross proceeds for Immix. The offering is scheduled to conclude around May 22, 2026, pending the fulfillment of standard closing prerequisites.